Eversept Partners’s Karyopharm Therapeutics KPTI Stock Holding History

Eversept Partners’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.54M	Buy	+276,174	New	+$2.11M	0.08%	95
2025 Q3	–	Sell	-257,154	Closed	-$1.11M	–	95
2025 Q2	$1.11M	Hold	257,154	–	–	0.1%	61
2025 Q1	$962K	Buy	257,154 +117,904	+85%	+$1.01M	0.1%	51
2024 Q4	$1.41M	Sell	139,250 -230,609	-62%	-$2.79M	0.13%	58
2024 Q3	$4.6M	Buy	369,859 +37,380	+11%	+$465K	0.32%	41
2024 Q2	$4.33M	Sell	332,479 -1,942	-0.6%	-$32.2K	0.3%	49
2024 Q1	$7.57M	Buy	+334,421	New	+$5.86M	0.51%	35

Other funds holding KPTI

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Eversept Partners's KPTI Position: Q1 2026 in Review

Eversept Partners opened a new position in Karyopharm Therapeutics (KPTI) in Q1 2026: 276,174 shares worth $1.54M. The stake represents 0.08% of the portfolio and ranks #95 among its holdings. This is a return to the name: Eversept Partners previously reported a position in KPTI as recently as Q2 2025.

Eversept Partners first reported a position in KPTI in Q1 2024 and has held it in 7 quarters since. The position peaked at $7.57M in Q1 2024. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

Eversept Partners held 276,174 shares of Karyopharm Therapeutics worth $1.54M as of Q1 2026.
Karyopharm Therapeutics was a new Eversept Partners position in Q1 2026.
Karyopharm Therapeutics made up 0.08% of Eversept Partners's portfolio in Q1 2026, its #95 holding.
Eversept Partners first reported a position in Karyopharm Therapeutics in Q1 2024 and has held it in 7 quarters since.
Eversept Partners's Karyopharm Therapeutics position peaked at $7.57M in Q1 2024.
77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Eversept Partners's 13F filing for Q1 2026, filed 15 May 2026.